

CLAIMS

1. A hemostatic material comprising as an effective ingredient thrombin and fibrinogen characterized in that a bioabsorbable synthetic nonwoven fabric is used as a supporting material.

2. The hemostatic material according to claim 1, wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.

3. The hemostatic material according to claim 1 or 2, wherein said bioabsorbable synthetic nonwoven fabric is a nonwoven fabric made of a material of polyglycolic acid.

4. The hemostatic material according to any of claims 1 to 3, wherein the bioabsorbable synthetic nonwoven fabric previously holds at least thrombin among thrombin and fibrinogen.

5. The hemostatic material according to any of claims 1 to 4, wherein said hemostatic material comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

6. The hemostatic material according to any of claims 1 to 5, wherein thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

7. Use of a combination of a bioabsorbable synthetic nonwoven fabric as a supporting material and thrombin and fibrinogen as an effective ingredient for a hemostatic material.

5 8. The use according to claim 7, wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.

10 9. The use according to claim 7 or 8, wherein said bioabsorbable synthetic nonwoven fabric is a nonwoven fabric made of a material of polyglycolic acid.

10. The use according to any of claims 7 to 9, wherein said hemostatic material comprises at least one
15 additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

11. The use according to claim 10, wherein said Factor XIII is added to fibrinogen.

12. The use according to any of claims 7 to 11,
20 wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

13. Use of a combination of a bioabsorbable synthetic nonwoven fabric holding thrombin as an effective ingredient,
25 and fibrinogen as an effective ingredient for a hemostatic

material.

14. The use according to claim 13, wherein said bioabsorbable synthetic nonwoven fabric holding thrombin as an effective ingredient is prepared by the steps of
5 immersing a bioabsorbable synthetic nonwoven fabric into a solution containing thrombin and of lyophilizing the obtained nonwoven fabric.

15. The use according to claim 13 or 14, wherein said bioabsorbable synthetic nonwoven fabric is made of a
10 material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.

16. The use according to any of claims 13 to 15, wherein said bioabsorbable synthetic nonwoven fabric is a
15 nonwoven fabric made of a material of polyglycolic acid.

17. The use according to any of claims 13 to 16, wherein said hemostatic material comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

20 18. The use according to claim 17, wherein said calcium chloride is fixed to the bioabsorbable synthetic nonwoven fabric together with thrombin.

19. The use according to claim 17 or 18, wherein said Factor XIII is added to fibrinogen.

25 20. The use according to any of claims 13 to 19,

wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

21. A hemostatic kit comprising a bioabsorbable
5 synthetic nonwoven fabric holding thrombin as an effective ingredient, and a container comprising fibrinogen as an effective ingredient.

22. The hemostatic kit according to claim 21, wherein
10 said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.

23. The hemostatic kit according to claim 21 or 22,
15 wherein said bioabsorbable synthetic nonwoven fabric is a nonwoven fabric made of a material of polyglycolic acid.

24. The hemostatic kit according to any of claims 21 to 23, wherein said hemostatic kit comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

20 25. The hemostatic kit according to claim 24, wherein said calcium chloride is added to the bioabsorbable synthetic nonwoven fabric as an additive for thrombin.

26. The hemostatic kit according to claim 24 or 25,
25 wherein said Factor XIII is included in a container comprising fibrinogen.

27. The hemostatic kit according to any of claims 21 to 26, wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

5 28. The hemostatic kit according to any of claims 21 to 27, wherein said bioabsorbable synthetic nonwoven fabric holding thrombin is prepared by the steps of immersing a bioabsorbable synthetic nonwoven fabric into a solution containing thrombin and of lyophilizing the obtained
10 nonwoven fabric.

29. A hemostatic kit comprising a bioabsorbable synthetic nonwoven fabric as a substrate, a container comprising thrombin as an effective ingredient and a container comprising fibrinogen as an effective ingredient.

15 30. The hemostatic kit according to claim 29, wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.

20 31. The hemostatic kit according to claim 29 or 30, wherein said bioabsorbable synthetic nonwoven fabric is a nonwoven fabric made of a material of polyglycolic acid.

32. The hemostatic kit according to any of claims 29 to 31, wherein said hemostatic kit comprises at least one
25 additive selected from Factor XIII, a protease inhibitor,

or calcium chloride.

33. The hemostatic kit according to claim 32, wherein said Factor XIII is included in a container comprising fibrinogen.

5 34. The hemostatic kit according to any of claims 29 to 33, wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.